Evaluation of risk prediction updates from commercial genome-wide scans
about
Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities. Background Document to the ESHG recommendations on genetic testing and common disordersUsers' motivations to purchase direct-to-consumer genome-wide testing: an exploratory study of personal storiesInternet-Based Direct-to-Consumer Genetic Testing: A Systematic ReviewIs genetic testing useful to predict type 2 diabetes?Reclassification of genetic-based risk predictions as GWAS data accumulate.Personal genome testing: test characteristics to clarify the discourse on ethical, legal and societal issuesPractical considerations to guide development of access controls and decision support for genetic information in electronic medical recordsAn epidemiological perspective on the future of direct-to-consumer personal genome testing.Informational content, literacy demands, and usability of websites offering health-related genetic tests directly to consumers.Role of genomics in cardiovascular medicine.The sense and nonsense of direct-to-consumer genetic testing for cardiovascular disease.Personalizing health care: feasibility and future implications.Risk assessment tools for identifying individuals at risk of developing type 2 diabetes.Genomic risk profiling: attitudes and use in personal and clinical care of primary care physicians who offer risk profiling.Motivations and perceptions of early adopters of personalized genomics: perspectives from research participants.Improved risk prediction for Crohn's disease with a multi-locus approach.Health care providers and direct-to-consumer access and advertising of genetic testing in the United StatesGenome paths: a way to personalized and predictive medicineInformed choice in direct-to-consumer genetic testing (DTCGT) websites: a content analysis of benefits, risks, and limitations.Legislation on direct-to-consumer genetic testing in seven European countries.A randomized trial of genetic information for personalized nutritionUse of genomic panels to determine risk of developing type 2 diabetes in the general population: a targeted evidence-based review.Practical issues in building risk-predicting models for complex diseasesPredicting risk of type 2 diabetes mellitus with genetic risk models on the basis of established genome-wide association markers: a systematic reviewIssues surrounding the health economic evaluation of genomic technologies.Type 2 diabetes and obesity: genomics and the clinic.Variations in predicted risks in personal genome testing for common complex diseasesIs there a doctor in the house? : The presence of physicians in the direct-to-consumer genetic testing context.Multigenic condition risk assessment in direct-to-consumer genomic services.Use of reclassification for assessment of improved prediction: an empirical evaluation.Size of the direct-to-consumer genomic testing market.Giving and withholding of information following genomic screening: challenges identified in a study of primary care physicians in Estonia.Direct-to-consumer personal genomic testing: a case study and practical recommendations for “genomic counseling”.Direct-to-consumer genetic testing: regulating offer or use?Direct-to-consumer pharmacogenomic testing
P2860
Q22330767-8BBC2D63-DD0B-42E8-90D2-C2741E97FEB8Q24635266-4200E5BF-CFF6-4F0B-A0CE-0C47136FC188Q26775070-FBC6E43F-16F8-466E-BF3D-9EDEED62C862Q26859442-6BF96C6E-E432-4B92-ACB0-E2CF34688E65Q31046674-38738DD5-FBD0-4025-A003-AC3082FF554DQ33932189-2ACAD9A0-1117-4C58-BE73-AB763AE591A8Q34065138-D97969C7-83C8-41E8-9072-B997018FEEC0Q34344701-36F6A5F7-61E0-4AD0-A81B-1501A537A621Q34379754-31257F93-4B3F-4E2F-BAF5-AFEBB79E519AQ34444807-068F0323-0BC0-4869-8D17-0323EB4E8A28Q34579841-8F78EDED-6A29-4784-AC48-1463AB250BE5Q34938911-4E51F594-0375-46AB-89E8-CBD586F59E48Q35095114-59C26EDB-8545-4FD6-9585-61FDAFDDDC09Q35113219-D74AD609-2350-49F6-B4E4-50490C34C5F6Q35576348-1B0FA543-8ECD-46FA-8039-7327C589C0A6Q35816613-C7EF9488-0228-409B-8656-EFBA98AE8D55Q35907523-546D1281-C409-4890-8543-9A5BD9C32FE3Q35944283-9672CA3B-72B2-4DA1-98EB-3ADA121F5E18Q35946640-FC3A5A80-C150-433F-8545-F7FA4C90E547Q36035698-A3401535-7392-46B4-B5C4-C24EFC4C3B67Q36250140-20DC2362-EC6B-4E5C-9FB2-B5C7E2F079A3Q36384522-FA486D18-B703-4F79-92D1-EB56BAC42257Q36938246-88683B02-6731-4ED9-BA05-1DAA5E62193EQ37220830-E7C092C4-B549-49D5-832D-D17B29C56AD8Q37541151-43882E1D-90AA-4D52-B1C4-57AA723D8AB1Q37885799-C3F0CEA0-C36E-40FC-8E20-DB1745683ED0Q39395332-8303E97B-DF86-4E35-BC17-64E2E550436AQ41959048-2000994D-0375-4751-BC16-56A05A24D92EQ46691615-D07297F5-3655-46D7-8A5C-A437B340D939Q46938393-5C72A720-02B1-4630-AA75-9486019B89E1Q47419984-0CB48427-6621-4107-AFFF-2E0661F57EEFQ50986179-9001BA5D-C15C-44D2-8026-191E6AD56455Q51818581-EA21FCC0-BED7-49E5-8B4A-5EC645296838Q57238635-DEDA1BFE-8A76-4191-BE0A-CC01B2FB5E1CQ57238650-38953050-07D9-425F-85F9-4E45DF39015C
P2860
Evaluation of risk prediction updates from commercial genome-wide scans
description
wetenschappelijk artikel
@nl
наукова стаття, опублікована в липні 2009
@uk
name
Evaluation of risk prediction updates from commercial genome-wide scans
@en
Evaluation of risk prediction updates from commercial genome-wide scans
@nl
type
label
Evaluation of risk prediction updates from commercial genome-wide scans
@en
Evaluation of risk prediction updates from commercial genome-wide scans
@nl
prefLabel
Evaluation of risk prediction updates from commercial genome-wide scans
@en
Evaluation of risk prediction updates from commercial genome-wide scans
@nl
P2093
P2860
P50
P1433
P1476
Evaluation of risk prediction updates from commercial genome-wide scans
@en
P2093
André g Uitterlinden
Cornelia M Van Duijn
Eric J G Sijbrands
Jacqueline C M Witteman
Mandy Van Hoek
P2860
P2888
P304
P356
10.1097/GIM.0B013E3181B13A4F
P407
P577
2009-07-25T00:00:00Z
P6179
1010863631